These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2429533)

  • 1. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T; Wakabayashi A; Kaneko S; Kurita T
    Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
    Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
    Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia.
    Matsumoto S; Hanai T; Matsui T; Oka M; Tanaka M; Uemura H
    Phytother Res; 2010 Feb; 24(2):301-3. PubMed ID: 19585469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients].
    Tamaki M; Nakashima M; Nishiyama R; Ikeda H; Hiura M; Kanaoka T; Nakano T; Hayashi T; Ogawa O
    Hinyokika Kiyo; 2008 Jun; 54(6):435-45. PubMed ID: 18634442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.
    Ishigooka M; Hashimoto T; Hayami S; Tomaru M; Nakada T; Mitobe K
    Int Urol Nephrol; 1995; 27(1):61-6. PubMed ID: 7542229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 9. [Conservative treatment of benign prostatic hypertrophy--clinical effects of increased administration of Hachimijiogan and the relation between these effects and the "Sho" of Chinese medicine].
    Yachiku S; Kaneko S; Matsuura T; Akiyama T; Kurita T
    Hinyokika Kiyo; 1985 Mar; 31(3):545-51. PubMed ID: 2411117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.
    Sugimoto M; Oka M; Tsunemori H; Yamashita M; Kakehi Y
    Prostate; 2011 Mar; 71(4):438-44. PubMed ID: 21254154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of voiding disorders and conservative pharmacological treatment of benign prostatic hypertrophy].
    Park YC; Takada M; Sugiyama T; Matsuura T; Kaneko S; Akiyama T; Kurita T; Yachiku S
    Hinyokika Kiyo; 1986 Nov; 32(11):1576-83. PubMed ID: 2435121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy].
    Sonoda T; Endo H; Maru A; Sasaki K; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T
    Hinyokika Kiyo; 1985 Mar; 31(3):553-62. PubMed ID: 2411118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of Cernilton on benign prostatic hyperplasia].
    Ueda K; Jinno H; Tsujimura S
    Hinyokika Kiyo; 1985 Jan; 31(1):187-91. PubMed ID: 2581428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy--with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography].
    Yoshida H; Haraguchi C; Ogawa Y; Kawai N; Ohyama M; Higaki Y; Saitoh T; Imamura K
    Hinyokika Kiyo; 1983 Nov; 29(11):1419-26. PubMed ID: 6203377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the phytotherapeutic agent Eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate.
    Oka M; Ueda M; Oyama T; Kyotani J; Tanaka M
    Prostate; 2009 Sep; 69(13):1404-10. PubMed ID: 19489033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].
    Kogawa T; Yanagiya H; Takashima T; Higashino I; Kudo T; Suzuki T; Mikuni T; Kido K; Tsukui A; Yagihashi Y
    Hinyokika Kiyo; 1993 Mar; 39(3):281-7. PubMed ID: 7685143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of Cernilton in benign prostatic hypertrophy].
    Hayashi J; Mitsui H; Yamakawa G; Suga A; Kai A; Shimabukuro T; Yanagi K; Fujisawa S; Takihara H; Kaneda Y
    Hinyokika Kiyo; 1986 Jan; 32(1):135-41. PubMed ID: 2421560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy].
    Horii A; Iwai S; Maekawa M; Tsujita M
    Hinyokika Kiyo; 1985 Apr; 31(4):739-46. PubMed ID: 2412423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring the effectiveness of conservative treatment of benign prostatic hypertrophy by means of uroflowmetry].
    Tunn U; Senge T
    Z Urol Nephrol; 1978 Aug; 71(8):521-8. PubMed ID: 83057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of prostatic hypertrophy with eviprostat].
    Kubo Y; Inoue S; Ono T; Yasui A
    Hinyokika Kiyo; 1966 Dec; 12(12):1463-7. PubMed ID: 4167083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.